Whole genome characterisation of chemoresistant ovarian cancer [NanoString miRNA]
收藏官方服务：
资源简介：
Whole genome characterisation of chemoresistant ovarian cancer [NanoString miRNA]
应用场景：
创建时间：
2015-05-19
相关数据集
Additional file 8 of Genome-wide small RNA profiling reveals tiller development in tall fescue (Festuca arundinacea Schreb)
Additional file 8. Differential expression of miRNAs between Ch-3 and Ch-5 tall fescue.
Figshare2024-02-29 更新50
Exploring changes in miRNA expression levels in bone marrow mesenchymal stem cells under dexamethasone treatment using miRNA sequencing. Exploring changes in miRNA expression levels in bone marrow mesenchymal stem cells under dexamethasone treatment using miRNA sequencing
In the progression of glucocorticoids (GCs) induced osteonecrosis of the femoral head (ONFH), miRNAs have important regulatory role and is involved in many biological processes. In this current study,
NIAID Data Ecosystem20
DataSheet9_Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma.ZIP
SHP2 mediates signaling from multiple receptor tyrosine kinases (RTKs) to extracellular signal-regulated kinase (ERK) and Ser and Thr kinase AKT, and its inhibitors offer an unprecedented opportunity
NIAID Data Ecosystem10
Loss of IFN-g signaling in tumor cells associates with primary resistance to anti-CTLA-4 therapy
"Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-?,
NIAID Data Ecosystem40
Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]. Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]
Secondary trastuzumab resistance represents an evolutionary adaptation of HER2-positive breast cancer during anti-HER2 treatment. Most current studies have uncovered the alternations of HER2 and assoc
NIAID Data Ecosystem20
